Skip to main content
Erschienen in: Current Urology Reports 1/2012

01.02.2012 | New Techniques: Imaging (A Atala, Section Editor)

Evaluation of Treatment Response in Patients with Metastatic Renal Cell Carcinoma: Role of State-of-the-Art Cross-Sectional Imaging

verfasst von: Venkata S. Katabathina, Nathalie Lassau, Ivan Pedrosa, Chaan S. Ng, Srinivasa R. Prasad

Erschienen in: Current Urology Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Recent advances in genetics and oncology have led to development of a wide array of molecular therapeutics in the management of patients with metastatic renal cell carcinoma. These drugs have revolutionized the treatment of advanced disease by significantly improving patient outcomes. State-of-the-art cross-sectional imaging techniques play a seminal role in the evaluation of treatment response by providing reproducible, objective data, thereby permitting accurate quantification of tumor burden. Evolving functional imaging techniques such as perfusion and diffusion studies continue to advance the technology beyond assessing changes in tumor size and morphology.
Literatur
2.
Zurück zum Zitat Ather MH, Masood N, Siddiqui T. Current management of advanced and metastatic renal cell carcinoma. Urol J. 2010;7:1–9.PubMed Ather MH, Masood N, Siddiqui T. Current management of advanced and metastatic renal cell carcinoma. Urol J. 2010;7:1–9.PubMed
3.
Zurück zum Zitat Brugarolas J. Renal-cell carcinoma–molecular pathways and therapies. N Engl J Med. 2007;356:185–7.PubMedCrossRef Brugarolas J. Renal-cell carcinoma–molecular pathways and therapies. N Engl J Med. 2007;356:185–7.PubMedCrossRef
4.
Zurück zum Zitat Cho D, Signoretti S, Regan M, et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007;13:758s–63s.PubMedCrossRef Cho D, Signoretti S, Regan M, et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007;13:758s–63s.PubMedCrossRef
6.
Zurück zum Zitat Herrmann E, Bierer S, Wulfing C. Update on systemic therapies of metastatic renal cell carcinoma. World J Urol. 2010;28:303–9.PubMedCrossRef Herrmann E, Bierer S, Wulfing C. Update on systemic therapies of metastatic renal cell carcinoma. World J Urol. 2010;28:303–9.PubMedCrossRef
7.
Zurück zum Zitat Shanbhogue AK, Karnad AB, Prasad SR. Tumor response evaluation in oncology: current update. J Comput Assist Tomogr. 2010;34:479–84.PubMedCrossRef Shanbhogue AK, Karnad AB, Prasad SR. Tumor response evaluation in oncology: current update. J Comput Assist Tomogr. 2010;34:479–84.PubMedCrossRef
8.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef
9.
Zurück zum Zitat van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al. Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol. 2010;5:95–112.PubMedCrossRef van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al. Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol. 2010;5:95–112.PubMedCrossRef
10.
Zurück zum Zitat •• van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al.: Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010;102:803–809. This study demonstrated the drawbacks of RECIST criteria in response evaluation assessment of metastatic RCC to antiangiogenic therapy. •• van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al.: Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010;102:803–809. This study demonstrated the drawbacks of RECIST criteria in response evaluation assessment of metastatic RCC to antiangiogenic therapy.
11.
Zurück zum Zitat Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase iii trial. Lancet. 2008;372:449–56.PubMedCrossRef Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase iii trial. Lancet. 2008;372:449–56.PubMedCrossRef
12.
Zurück zum Zitat Abel EJ, Culp SH, Tannir NM, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2011;59:10–5.PubMedCrossRef Abel EJ, Culp SH, Tannir NM, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2011;59:10–5.PubMedCrossRef
13.
Zurück zum Zitat Thiam R, Fournier LS, Trinquart L, et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol. 2010;21:936–41.PubMedCrossRef Thiam R, Fournier LS, Trinquart L, et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol. 2010;21:936–41.PubMedCrossRef
14.
Zurück zum Zitat Krajewski KM, Guo M, Van den Abbeele AD, et al. Comparison of four early posttherapy imaging changes (Eptic; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol. 2011;59:856–62.PubMedCrossRef Krajewski KM, Guo M, Van den Abbeele AD, et al. Comparison of four early posttherapy imaging changes (Eptic; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol. 2011;59:856–62.PubMedCrossRef
15.
Zurück zum Zitat Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.PubMedCrossRef Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.PubMedCrossRef
16.
Zurück zum Zitat Hittinger M, Staehler M, Schramm N, et al.: Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy. Urol Oncol 2011. Hittinger M, Staehler M, Schramm N, et al.: Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy. Urol Oncol 2011.
17.
Zurück zum Zitat Nathan PD, Vinayan A, Stott D, et al. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther. 2010;9:15–9.PubMedCrossRef Nathan PD, Vinayan A, Stott D, et al. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther. 2010;9:15–9.PubMedCrossRef
18.
Zurück zum Zitat Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol. 2010;194:157–65.PubMedCrossRef Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol. 2010;194:157–65.PubMedCrossRef
19.
Zurück zum Zitat •• Smith AD, Shah SN, Rini BI, et al.: Morphology, attenuation, size, and structure (MASS) criteria: Assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010;194:1470–1478. This reference proposed the new response evaluation criteria (MASS) for metastatic RCC patients receiving targeted therapies. •• Smith AD, Shah SN, Rini BI, et al.: Morphology, attenuation, size, and structure (MASS) criteria: Assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010;194:1470–1478. This reference proposed the new response evaluation criteria (MASS) for metastatic RCC patients receiving targeted therapies.
20.
Zurück zum Zitat Goh V, Ganeshan B, Nathan P, et al. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology. 2011;261:165–71.PubMedCrossRef Goh V, Ganeshan B, Nathan P, et al. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology. 2011;261:165–71.PubMedCrossRef
21.
Zurück zum Zitat Kambadakone AR, Sahani DV. Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am. 2009;47:161–78.PubMedCrossRef Kambadakone AR, Sahani DV. Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am. 2009;47:161–78.PubMedCrossRef
22.
Zurück zum Zitat •• Fournier LS, Oudard S, Thiam R, et al.: Metastatic renal carcinoma: Evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 2010;256:511–518. The authors evaluated the role of perfusion CT in early response assessment of metastatic RCC to antiangiogenic therapy. •• Fournier LS, Oudard S, Thiam R, et al.: Metastatic renal carcinoma: Evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 2010;256:511–518. The authors evaluated the role of perfusion CT in early response assessment of metastatic RCC to antiangiogenic therapy.
23.
Zurück zum Zitat Chen Y, Zhang J, Dai J, et al. Angiogenesis of renal cell carcinoma: perfusion CT findings. Abdom Imaging. 2010;35:622–8.PubMedCrossRef Chen Y, Zhang J, Dai J, et al. Angiogenesis of renal cell carcinoma: perfusion CT findings. Abdom Imaging. 2010;35:622–8.PubMedCrossRef
24.
Zurück zum Zitat Ng CS, Wang X, Faria SC, et al. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. AJR Am J Roentgenol. 2010;194:166–71.PubMedCrossRef Ng CS, Wang X, Faria SC, et al. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. AJR Am J Roentgenol. 2010;194:166–71.PubMedCrossRef
25.
Zurück zum Zitat •• Rosen MA, Schnall MD: Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 2007;13:770 s-776s. This reference showed the importance of DCE-MRI in assessing RCC vascularity and vascular effects of targeted therapies. •• Rosen MA, Schnall MD: Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 2007;13:770 s-776s. This reference showed the importance of DCE-MRI in assessing RCC vascularity and vascular effects of targeted therapies.
26.
Zurück zum Zitat Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2003;17:509–20.PubMedCrossRef Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2003;17:509–20.PubMedCrossRef
27.
Zurück zum Zitat Harry VN, Semple SI, Parkin DE, et al. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol. 2010;11:92–102.PubMedCrossRef Harry VN, Semple SI, Parkin DE, et al. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol. 2010;11:92–102.PubMedCrossRef
28.
Zurück zum Zitat Pedrosa I, Alsop DC, Rofsky NM. Magnetic resonance imaging as a biomarker in renal cell carcinoma. Cancer. 2009;115:2334–45.PubMedCrossRef Pedrosa I, Alsop DC, Rofsky NM. Magnetic resonance imaging as a biomarker in renal cell carcinoma. Cancer. 2009;115:2334–45.PubMedCrossRef
29.
Zurück zum Zitat O'Connor JP, Jackson A, Parker GJ, et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer. 2007;96:189–95.PubMedCrossRef O'Connor JP, Jackson A, Parker GJ, et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer. 2007;96:189–95.PubMedCrossRef
30.
Zurück zum Zitat Jackson A, O'Connor JP, Parker GJ, et al. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res. 2007;13:3449–59.PubMedCrossRef Jackson A, O'Connor JP, Parker GJ, et al. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res. 2007;13:3449–59.PubMedCrossRef
31.
Zurück zum Zitat Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther. 2008;7:496–501.PubMedCrossRef Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther. 2008;7:496–501.PubMedCrossRef
32.
Zurück zum Zitat Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008;26:4572–8.PubMedCrossRef Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008;26:4572–8.PubMedCrossRef
33.
Zurück zum Zitat Hillman GG, Singh-Gupta V, Al-Bashir AK, et al. Monitoring sunitinib-induced vascular effects to optimize radiotherapy combined with soy isoflavones in murine xenograft tumor. Transl Oncol. 2011;4:110–21.PubMed Hillman GG, Singh-Gupta V, Al-Bashir AK, et al. Monitoring sunitinib-induced vascular effects to optimize radiotherapy combined with soy isoflavones in murine xenograft tumor. Transl Oncol. 2011;4:110–21.PubMed
34.
Zurück zum Zitat Martirosian P, Boss A, Schraml C, et al. Magnetic resonance perfusion imaging without contrast media. Eur J Nucl Med Mol Imaging. 2010;37 Suppl 1:S52–64.PubMedCrossRef Martirosian P, Boss A, Schraml C, et al. Magnetic resonance perfusion imaging without contrast media. Eur J Nucl Med Mol Imaging. 2010;37 Suppl 1:S52–64.PubMedCrossRef
35.
Zurück zum Zitat Pedrosa I, Rafatzand K, Robson P, Wagner AA, Atkins MB, Rofsky NM, Alsop DC: Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experience. Eur Radiol 2011. Pedrosa I, Rafatzand K, Robson P, Wagner AA, Atkins MB, Rofsky NM, Alsop DC: Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experience. Eur Radiol 2011.
36.
Zurück zum Zitat De Bazelaire C, Rofsky NM, Duhamel G, et al. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). Acad Radiol. 2005;12:347–57.PubMedCrossRef De Bazelaire C, Rofsky NM, Duhamel G, et al. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). Acad Radiol. 2005;12:347–57.PubMedCrossRef
37.
Zurück zum Zitat •• de Bazelaire C, Alsop DC, George D, et al.: Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK 787/zk 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 2008;14:5548–5554. The authors evaluated ASL-MRI in evaluating blood flow change after antiangiogenic therapy to metastatic RCC. •• de Bazelaire C, Alsop DC, George D, et al.: Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK 787/zk 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 2008;14:5548–5554. The authors evaluated ASL-MRI in evaluating blood flow change after antiangiogenic therapy to metastatic RCC.
38.
Zurück zum Zitat Schor-Bardach R, Alsop DC, Pedrosa I, et al. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology. 2009;251:731–42.PubMedCrossRef Schor-Bardach R, Alsop DC, Pedrosa I, et al. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology. 2009;251:731–42.PubMedCrossRef
39.
Zurück zum Zitat Patterson DM, Padhani AR, Collins DJ. Technology insight: water diffusion MRI–a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol. 2008;5:220–33.PubMedCrossRef Patterson DM, Padhani AR, Collins DJ. Technology insight: water diffusion MRI–a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol. 2008;5:220–33.PubMedCrossRef
40.
Zurück zum Zitat Byun WM, Shin SO, Chang Y, et al. Diffusion-weighted MR imaging of metastatic disease of the spine: assessment of response to therapy. AJNR Am J Neuroradiol. 2002;23:906–12.PubMed Byun WM, Shin SO, Chang Y, et al. Diffusion-weighted MR imaging of metastatic disease of the spine: assessment of response to therapy. AJNR Am J Neuroradiol. 2002;23:906–12.PubMed
41.
Zurück zum Zitat Wang H, Cheng L, Zhang X, et al. Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 t. Radiology. 2010;257:135–43.PubMedCrossRef Wang H, Cheng L, Zhang X, et al. Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 t. Radiology. 2010;257:135–43.PubMedCrossRef
42.
Zurück zum Zitat Razek AA, Farouk A, Mousa A, et al. Role of diffusion-weighted magnetic resonance imaging in characterization of renal tumors. J Comput Assist Tomogr. 2011;35:332–6.PubMedCrossRef Razek AA, Farouk A, Mousa A, et al. Role of diffusion-weighted magnetic resonance imaging in characterization of renal tumors. J Comput Assist Tomogr. 2011;35:332–6.PubMedCrossRef
43.
Zurück zum Zitat Huang CF, Chiou SY, Wu MF, et al. Apparent diffusion coefficients for evaluation of the response of brain tumors treated by gamma knife surgery. J Neurosurg. 2010;113(Suppl):97–104.PubMed Huang CF, Chiou SY, Wu MF, et al. Apparent diffusion coefficients for evaluation of the response of brain tumors treated by gamma knife surgery. J Neurosurg. 2010;113(Suppl):97–104.PubMed
44.
Zurück zum Zitat Roth Y, Tichler T, Kostenich G, et al. High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology. 2004;232:685–92.PubMedCrossRef Roth Y, Tichler T, Kostenich G, et al. High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology. 2004;232:685–92.PubMedCrossRef
45.
Zurück zum Zitat Morgan VA, Riches SF, Thomas K, et al. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol. 2011;84:31–7.PubMedCrossRef Morgan VA, Riches SF, Thomas K, et al. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol. 2011;84:31–7.PubMedCrossRef
46.
Zurück zum Zitat Peronneau P, Lassau N, Leguerney I, et al. Contrast ultrasonography: necessity of linear data processing for the quantification of tumor vascularization. Ultraschall Med. 2010;31:370–8.PubMedCrossRef Peronneau P, Lassau N, Leguerney I, et al. Contrast ultrasonography: necessity of linear data processing for the quantification of tumor vascularization. Ultraschall Med. 2010;31:370–8.PubMedCrossRef
47.
Zurück zum Zitat Williams R, Hudson JM, Lloyd BA, et al. Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy. Radiology. 2011;260:581–90.PubMedCrossRef Williams R, Hudson JM, Lloyd BA, et al. Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy. Radiology. 2011;260:581–90.PubMedCrossRef
48.
Zurück zum Zitat Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced doppler ultrasound. Eur J Cancer. 2006;42:2472–9.PubMedCrossRef Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced doppler ultrasound. Eur J Cancer. 2006;42:2472–9.PubMedCrossRef
49.
Zurück zum Zitat Escudier B, Lassau N, Angevin E, et al. Phase i trial of sorafenib in combination with ifn alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res. 2007;13:1801–9.PubMedCrossRef Escudier B, Lassau N, Angevin E, et al. Phase i trial of sorafenib in combination with ifn alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res. 2007;13:1801–9.PubMedCrossRef
50.
Zurück zum Zitat Lassau N, Lamuraglia M, Chami L, et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol. 2006;187:1267–73.PubMedCrossRef Lassau N, Lamuraglia M, Chami L, et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol. 2006;187:1267–73.PubMedCrossRef
51.
Zurück zum Zitat Lassau N, Lamuraglia M, Vanel D, et al. Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol. 2005;16:1054–60.PubMedCrossRef Lassau N, Lamuraglia M, Vanel D, et al. Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol. 2005;16:1054–60.PubMedCrossRef
52.
Zurück zum Zitat Cosgrove D, Lassau N. Imaging of perfusion using ultrasound. Eur J Nucl Med Mol Imaging. 2010;37 Suppl 1:S65–85.PubMedCrossRef Cosgrove D, Lassau N. Imaging of perfusion using ultrasound. Eur J Nucl Med Mol Imaging. 2010;37 Suppl 1:S65–85.PubMedCrossRef
53.
Zurück zum Zitat Lassau N, Koscielny S, Chami L, et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification–preliminary results. Radiology. 2011;258:291–300.PubMedCrossRef Lassau N, Koscielny S, Chami L, et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification–preliminary results. Radiology. 2011;258:291–300.PubMedCrossRef
54.
Zurück zum Zitat Lassau N, Chami L, Koscielny S, et al.: Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in gist patients treated with masatinib. Invest New Drugs 2010. Lassau N, Chami L, Koscielny S, et al.: Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in gist patients treated with masatinib. Invest New Drugs 2010.
55.
Zurück zum Zitat •• Lassau N, Koscielny S, Albiges L, et al.: Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 2010;16:1216–1225. They evaluated DCE-US in early evaluation of treatment response after sunitinib therapy to metastatic RCC. •• Lassau N, Koscielny S, Albiges L, et al.: Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 2010;16:1216–1225. They evaluated DCE-US in early evaluation of treatment response after sunitinib therapy to metastatic RCC.
56.
Zurück zum Zitat Lassau N, Chami L, Chebil M, et al. Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discov Med. 2011;11:18–24.PubMed Lassau N, Chami L, Chebil M, et al. Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discov Med. 2011;11:18–24.PubMed
57.
Zurück zum Zitat Michels J, Lassau N, Gross-Goupil M, et al. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs. 2010;28:690–3.PubMedCrossRef Michels J, Lassau N, Gross-Goupil M, et al. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs. 2010;28:690–3.PubMedCrossRef
58.
Zurück zum Zitat Casali PG, Blay JY. Soft tissue sarcomas: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v198–203.PubMedCrossRef Casali PG, Blay JY. Soft tissue sarcomas: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v198–203.PubMedCrossRef
59.
Zurück zum Zitat Piscaglia F, Nolsoe C, Dietrich CF, et al.: The EFSUMB guidelines and recommendations on the clinical practice of contrast enhanced ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med 2011. Piscaglia F, Nolsoe C, Dietrich CF, et al.: The EFSUMB guidelines and recommendations on the clinical practice of contrast enhanced ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med 2011.
60.
Zurück zum Zitat Majhail NS, Urbain JL, Albani JM, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol. 2003;21:3995–4000.PubMedCrossRef Majhail NS, Urbain JL, Albani JM, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol. 2003;21:3995–4000.PubMedCrossRef
61.
Zurück zum Zitat Lyrdal D, Boijsen M, Suurkula M, et al. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun. 2009;30:519–24.PubMedCrossRef Lyrdal D, Boijsen M, Suurkula M, et al. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun. 2009;30:519–24.PubMedCrossRef
62.
Zurück zum Zitat Minamimoto R, Nakaigawa N, Tateishi U, et al. Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by fdg pet/contrast-enhanced CT. Clin Nucl Med. 2010;35:918–23.PubMedCrossRef Minamimoto R, Nakaigawa N, Tateishi U, et al. Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by fdg pet/contrast-enhanced CT. Clin Nucl Med. 2010;35:918–23.PubMedCrossRef
63.
Zurück zum Zitat Revheim ME, Winge-Main AK, Hagen G, et al. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol). 2011;23:339–43.CrossRef Revheim ME, Winge-Main AK, Hagen G, et al. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol). 2011;23:339–43.CrossRef
64.
Zurück zum Zitat Middendorp M, Maute L, Sauter B, et al. Initial experience with 18f-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma. Ann Nucl Med. 2010;24:441–6.PubMedCrossRef Middendorp M, Maute L, Sauter B, et al. Initial experience with 18f-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma. Ann Nucl Med. 2010;24:441–6.PubMedCrossRef
65.
Zurück zum Zitat Hugonnet F, Fournier L, Medioni J, et al. Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month’s sunitinib, and therapeutic response: An 18f-fluoromisonidazole PET/CT study. J Nucl Med. 2011;52:1048–55.PubMedCrossRef Hugonnet F, Fournier L, Medioni J, et al. Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month’s sunitinib, and therapeutic response: An 18f-fluoromisonidazole PET/CT study. J Nucl Med. 2011;52:1048–55.PubMedCrossRef
Metadaten
Titel
Evaluation of Treatment Response in Patients with Metastatic Renal Cell Carcinoma: Role of State-of-the-Art Cross-Sectional Imaging
verfasst von
Venkata S. Katabathina
Nathalie Lassau
Ivan Pedrosa
Chaan S. Ng
Srinivasa R. Prasad
Publikationsdatum
01.02.2012
Verlag
Current Science Inc.
Erschienen in
Current Urology Reports / Ausgabe 1/2012
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-011-0233-x

Weitere Artikel der Ausgabe 1/2012

Current Urology Reports 1/2012 Zur Ausgabe

Kidney Diseases (G Ciancio, Section Editor)

Current Status of Robot-Assisted Partial Nephrectomy

New Techniques: Imaging (A Atala, Section Editor)

Value of Multiparametric MRI in the Work-up of Prostate Cancer

New Techniques: Imaging (A Atala, Section Editor)

Noncontrast Functional MRI of the Kidneys

Kidney Diseases (G Ciancio, Section Editor)

Stem Cells as a Therapeutic Approach to Chronic Kidney Diseases

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.